The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase i trials Journal Article

Authors: Iasonos, A.; Gounder, M.; Spriggs, D. R.; Gerecitano, J. F.; Hyman, D. M.; Zohar, S.; O'Quigley, J.
Article Title: The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase i trials
Abstract: The rate of observed dose-limiting toxicities (DLT) determines the maximum tolerated dose (MTD) in phase I trials. There are cases in which non-drug-related toxicities or other-cause toxicities (OCT) are flagged as DLTs, or vice versa, due to attribution errors. We aim to assess the impact of such errors on the final estimate of MTD. We compared the impact of attribution errors using 2 trial designs - the "3+3" dose-escalation scheme and the continual reassessment method (CRM). Two attribution errors are considered: when a DLT is classified as an OCT (type A error) and when an OCT is misclassified as a DLT (type B error). The impact of these errors on accuracy, patient safety, sample size, and study duration was evaluated by varying the probability of occurrence of each error through simulated trials. Under no errors, CRM is on average 35% more accurate than 3+3 in finding the true MTD. This improved accuracy is maintained in the presence of errors. At a 15% type B error rate, CRM recommends a dose within 2 levels of the true MTD 68% of the time, compared with 17% of the time using the 3+3 method. A DLT must be attributed as an OCT 30% of the time to increase the accuracy of 3+3; otherwise the method recommends a wrong dose approximately 75% of the time. CRM is more robust to toxicity attribution errors compared with the 3+3 as it uses information from all treated patients, leading to a more accurate MTD estimation at the frequency of attribution errors anticipated in phase I clinical trials. ©2012 AACR.
Keywords: controlled study; drug safety; recommended drug dose; unspecified side effect; accuracy; analytic method; drug dose escalation; statistical analysis; patient safety; maximum tolerated dose; phase 1 clinical trial; toxicity; medical error; dose calculation; drug; continual reassessment method
Journal Title: Clinical Cancer Research
Volume: 18
Issue: 19
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2012-10-01
Start Page: 5179
End Page: 5187
Language: English
DOI: 10.1158/1078-0432.ccr-12-0726
PROVIDER: scopus
PMCID: PMC3463734
PUBMED: 22825582
Notes: --- - "Export Date: 2 November 2012" - "CODEN: CCREF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Alexia Elia Iasonos
    179 Iasonos
  2. Mrinal M Gounder
    68 Gounder
  3. David Hyman
    181 Hyman
  4. David R Spriggs
    312 Spriggs